Various grades of @entity1412 represent precancerous states leading to the most common type of @entity420 with endometrial differentiation. Grades 1 and 2 are characterized by architectural abnormalities only (complex hyperplasia). They rarely progress to @entity189 . Grade 3 in addition is characterized by cytological atypicalities ( @entity1373 ) and shows a much higher progression rate into @entity189 . @entity1204 may originate from endometrial glandular epithelium and show endometrial differentiation, or from various types of metaplasias developing in the endometrium from pluripotent M  llerian epithelium. They then show endocervical or serous papillary differentiation. Because of their differences in spread, speed of growth and survival rates, it is important to subclassify these @entity1204 . Immunohistochemically, @entity420 with endometrial differentiation including adenoacanthomas and @entity1962 can be recognized by their coexpression of @entity10585 and @entity2277 , and by their negative reaction for @entity478 . Distinction from @entity420 with mucinous differentiation, including muceopidermoid @entity420 , is possible by their negative reaction for @entity2277 and by their positive reaction for @entity478 . On the other hand, @entity189 with mucinous differentiation primarily located in the endometrium can not be distinguished from those primarily located in the endocervix by immunohistochemistry; that distinction must be made topographically. The same holds true for @entity1358 of both locations. Over the past decade, @entity3079 and @entity1358 originating from the endometrium have increased, whereas @entity420 with endometrial differentiation have become less frequent. This shift is closely related to the altered postmenopausal hormone substitution with the addition of the synthetic gestagens. These apparently stimulate proliferation of endocervical epithelium not only in the endocervix, but also that arising in endocervical metaplasias of the endometrium.

[New cytogenetic classification of precancerous lesions and XXXX of the endometrium: possibilities and limits of immunohistochemical differentiation].

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinomas', 'Endometrial carcinomas'] @entity478 :: ('5670', 'Gene') :: ['CEA'] @entity3079 :: ('MESH:D002288', 'Disease') :: ['mucinous adenocarcinomas'] @entity1962 :: ('MESH:D018196', 'Disease') :: ['adenosquamous carcinomas'] @entity10585 :: ('3856', 'Gene') :: ['cytokeratin 8'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['atypical hyperplasia'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'carcinoma', 'invasive carcinoma'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['clear cell carcinomas'] @entity2277 :: ('7431', 'Gene') :: ['vimentin'] @entity1412 :: ('MESH:D011125', 'Disease') :: ['adenomatous hyperplasia'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma']
@entity189 :: (MESH:D002277,Disease) :: ['carcinomas']
